TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00871078

Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls

Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls

Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls

Intervention type: DEVICE
Intervention: Frequency Doubling Technology (FDT) perimeter
Description: 24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.

Intervention type: DEVICE
Intervention: Frequency Doubling Technology (FDT) perimeter
Description: 24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.

Intervention type: DEVICE
Intervention: Frequency Doubling Technology (FDT) perimeter
Description: 24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
Study: NCT01455480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: topical
Study: NCT00613106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZT-501
Description: Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
Study: NCT01459692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Exposure
Description: Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
Study: NCT04265131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: art therapy
Description: Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
Study: NCT00414375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation on Admission
Description: Laparoscopic appendectomy on admission

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage and Interval Appendectomy
Description: drainage with interval appendectomy
Study: NCT05236166

Intervention type: DRUG
Group type: OTHER
Intervention: Rapid withdrawal of antiepileptic
Description: Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide

Intervention type: DRUG
Group type: OTHER
Intervention: Slow withdrawal of antiepileptic
Description: Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide
Study: NCT02359656

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical treatment
Description: C1-C1 arthrodesis

Intervention type: OTHER
Group type: OTHER
Intervention: non operative treatment for odontoid non unions
Description: specific non operative treatment protocol
Study: NCT02209467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group balance training
Description: Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
Study: NCT01361984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol
Description: Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is \~9 minutes
Study: NCT01336946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking session
Description: A weekly supervised walking session (30 minutes) in a 10-week period.
Study: NCT03132922

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
Description: Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Description: Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
Study: NCT01361984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
Study: NCT02616731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin
Description: use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
Study: NCT00229593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestorone gel
Description: 2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestorone gel
Description: 2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestorone gel
Description: 2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestorone gel
Description: 2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestorone gel
Description: 2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: 100 mg Testosterone gel daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: 100 mg Testosterone gel daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: 100 mg Testosterone gel daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: 100 mg Testosterone gel daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: 100 mg Testosterone gel daily for 3 weeks
Study: NCT00969696

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8Mg a day of a sugar pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: 8mg of Galantamine
Study: NCT01216631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: intra-articular injection of methylprednisolone (80mg given at baseline only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: intra-articular injection of 100mg infliximab given at baseline only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
Study: NCT02747290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-BBN-RGD
Description: 68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
Study: NCT01942343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration
Study: NCT01809106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 60 mg /24 ore

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 25 microg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 35 microg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 40 mg /24 ore
Study: NCT01890070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnuts
Description: Italian hazelnuts from Piedmont with Protected Geographical Indication Certification

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnuts
Description: Italian hazelnuts from Piedmont with Protected Geographical Indication Certification

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnuts
Description: Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
Study: NCT05451225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Educational Campaign
Description: Correction Officers will be exposed to the Targeted Educational Campaign (TEC) with the aim to increase their knowledge about the early symptoms of psychosis, and how to make a referral to the Correction Health Services staff, their self-efficacy to detect symptoms of psychosis and make referrals, and their expectations about their ability to be successful in making that referral (and for referrals to result in beneficial outcomes).~Correction Officers will be approached and recruited during roll call and in the staff canteen where they take their meal breaks, or at a time/location agreed upon by the Department of Correction, to complete brief surveys at three different times; pre-exposure, after 6 months, and after 12 months from the beginning of the TEC.
Study: NCT05123170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injectable Solution [Dexdomitor]
Description: two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injectable Solution [Dexdomitor]
Description: two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Intravenous regional anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Intravenous regional anaesthesia
Study: NCT03833661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
Study: NCT01890070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnuts
Description: Italian hazelnuts from Piedmont with Protected Geographical Indication Certification

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red wine
Description: Italian Organic Red Wine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red wine
Description: Italian Organic Red Wine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red wine
Description: Italian Organic Red Wine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red wine
Description: Italian Organic Red Wine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Italian Organic Olive Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Italian Organic Olive Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Italian Organic Olive Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Italian Organic Olive Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild mixed greens
Description: Italian organic wild mixed greens

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild mixed greens
Description: Italian organic wild mixed greens

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild mixed greens
Description: Italian organic wild mixed greens

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild mixed greens
Description: Italian organic wild mixed greens
Study: NCT01570348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study: NCT04420676

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omnibiotic AAD
Description: Bacterial strains in Omni-Biotic® 10 AAD are Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 which are embedded in a matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate
Study: NCT04630535

Intervention type: PROCEDURE
Intervention: aorto-bifemoral bypass surgery
Description: aorto-bifemoral bypass surgery (Leriche syndrom, elective AAA repair)

Intervention type: PROCEDURE
Intervention: aorto-bifemoral bypass surgery
Description: aorto-bifemoral bypass surgery (Leriche syndrom, elective AAA repair)
Study: NCT02359188

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: 4 hours of transcutaneous vagal nerve stimulation
Study: NCT01570348

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT03971487

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosis and cognitive assessments
Description: Administration of MINI, PANSS and Quality of Living scales

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychosis and cognitive assessments
Description: Administration of MINI, PANSS and Quality of Living scales

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical and neuro-cognitive evaluations
Description: Physical, neurological and cognitive evaluations.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical and neuro-cognitive evaluations
Description: Physical, neurological and cognitive evaluations.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Safety labs and electrocardiogram
Description: Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Safety labs and electrocardiogram
Description: Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab infusion
Description: Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
Study: NCT00775541

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: One IV infusion of 2 gm vitamin C
Study: NCT02562482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VRC-PBSPLA043-00-VP
Description: VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
Study: NCT00517959

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Conformal radiotherapy
Description: SCRT

Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional radiotherapy
Study: NCT03657108

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Civasheet 60 Gy
Description: implantable proposed doses of Civasheet are 60 Gy
Study: NCT04420676

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate.
Study: NCT01378143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI
Description: OCZ103-OS is given in combination with Chemotherapy each cycle
Study: NCT03657108

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Civasheet 60 Gy
Description: implantable proposed doses of Civasheet are 60 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Civasheet 75 Gy
Description: implantable proposed doses of Civasheet are 75 Gy
Study: NCT05123170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Intravenous regional anaesthesia
Study: NCT03657108

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Civasheet 75 Gy
Description: implantable proposed doses of Civasheet are 75 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiation therapy
Description: 45 Gy in 25 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiation therapy
Description: 45 Gy in 25 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiation therapy
Description: 45 Gy in 25 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiation therapy
Description: 45 Gy in 25 fractions
Study: NCT04688970

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00003487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00679913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard pancreatoduodenectomy
Description: Standard pancreatoduodenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended pancreatoduodenectomy
Description: Extended pancreatoduodenectomy
Study: NCT02044549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: Oxycontin analogue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntometrine
Description: Uterotonins
Study: NCT00562770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: 900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
Study: NCT01890070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chestnut
Description: Italian Organic Chestnut

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chestnut
Description: Italian Organic Chestnut
Study: NCT03569085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
Study: NCT02776865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suprascapular nerve block
Description: 4ml 2% xylocaine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: patient received traditional physical therapy, including therapeutic exercise and stretch exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: patient received traditional physical therapy, including therapeutic exercise and stretch exercise
Study: NCT00562770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
Study: NCT03501537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft obtained from the palate and debridement of the peri-implant lesion
Description: granulation tissue debridement and grafting of a free gingival strip obtained from the palate
Study: NCT01727687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral training for crossing road
Description: behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
Study: NCT00576641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells
Study: NCT01032772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choices Plus
Description: Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Participants are provided with informational materials about healthy lifestyle and local resources.
Study: NCT02030314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: treatment of resistant hypertension in kidney transplant patients